Hainan Poly Pharm Co Ltd Market Cap ($73.10 Million)
Market Cap & Net Worth: Hainan Poly Pharm Co Ltd (300630)
Hainan Poly Pharm Co Ltd market cap. Hainan Poly Pharm Co Ltd (SHE:300630) has a market capitalization of $73.10 Million (CN¥499.57 Million) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #20257 globally and #4676 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Poly Pharm Co Ltd's stock price CN¥0.89 by its total outstanding shares 561308992 (561.31 Million). Also see how efficiently does Hainan Poly Pharm Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Hainan Poly Pharm Co Ltd Market Cap History (2017–2025)
Hainan Poly Pharm Co Ltd market cap history from 2017 to 2025. Data shows change from $1.78 Billion to $73.10 Million (-29.93% CAGR). Check latest Hainan Poly Pharm Co Ltd stock price today for real-time trading data and today's change.
Hainan Poly Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Poly Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hainan Poly Pharm Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.42x
Hainan Poly Pharm Co Ltd's market cap is 1.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.62x
Hainan Poly Pharm Co Ltd's market cap is 21.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.78 Billion | $324.83 Million | $98.40 Million | 5.49x | 18.12x |
| 2018 | $1.54 Billion | $623.90 Million | $181.43 Million | 2.47x | 8.50x |
| 2019 | $2.98 Billion | $950.10 Million | $301.15 Million | 3.14x | 9.90x |
| 2020 | $3.39 Billion | $1.19 Billion | $407.45 Million | 2.85x | 8.33x |
| 2021 | $4.47 Billion | $1.51 Billion | $416.60 Million | 2.97x | 10.74x |
| 2022 | $2.02 Billion | $1.81 Billion | $420.62 Million | 1.12x | 4.80x |
| 2023 | $1.86 Billion | $1.30 Billion | $85.92 Million | 1.42x | 21.62x |
Competitor Companies of 300630 by Market Capitalization
Companies near Hainan Poly Pharm Co Ltd in the global market cap rankings as of November 1, 2026. Also see Hainan Poly Pharm Co Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Hainan Poly Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Hainan Poly Pharm Co Ltd (2017–2025)
Market capitalization of Hainan Poly Pharm Co Ltd from 2017 to today. Between 2017 and today, Hainan Poly Pharm Co Ltd's market cap moved from $1.78 Billion to $ 73.10 Million, with a yearly change of -29.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CN¥73.10 Million | -86.93% |
| 2024 | CN¥559.35 Million | -69.89% |
| 2023 | CN¥1.86 Billion | -7.90% |
| 2022 | CN¥2.02 Billion | -54.91% |
| 2021 | CN¥4.47 Billion | +31.90% |
| 2020 | CN¥3.39 Billion | +13.83% |
| 2019 | CN¥2.98 Billion | +93.32% |
| 2018 | CN¥1.54 Billion | -13.54% |
| 2017 | CN¥1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On May 20th, 2026 the market cap of Hainan Poly Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $73.10 Million USD |
| MoneyControl | $73.10 Million USD |
| MarketWatch | $73.10 Million USD |
| marketcap.company | $73.10 Million USD |
| Reuters | $73.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more